Selenomethionine Se-75

Selenomethionine Se-75 is a radiopharmaceutical small molecule in which the sulfur atom of methionine is replaced by radioactive selenium (Se‑75). It is primarily used as a diagnostic aid for pancreas function determination and to investigate methionine metabolism, typically administered intravenously. The compound was first approved in 1973 and has reached phase IV clinical use. Its mechanism relies on the chemical similarity between selenium and sulfur, allowing it to be incorporated into metabolic pathways similar to natural methionine. After administration, Selenomethionine Se‑75 accumulates in tissues with active protein synthesis, such as the pancreas and liver, enabling imaging via gamma cameras due to its radioactivity. This property allows visualization of pancreatic tissue and detection of space‑occupying lesions based on altered uptake patterns[1][3][4][5].

Brand names

sethotope

Other names

l-selenomethionine